Search research articles
Contact Us
Filters
Showing results (1-10 of 174) with videos related to
Page
of 18
Sort By:
Cancer Cell
|
April 14, 2023
No rest for the wicked: Tumor cell senescence reshapes the immune microenvironment
Ann Hanna, Justin M Balko
Breast Cancer Research and Treatment
|
July 29, 2021
Breast cancer resistance mechanisms: challenges to immunotherapy
Ann Hanna, Justin M Balko
Breast Cancer Research and Treatment
|
August 10, 2010
Dead-box or black-box: is DDX1 a potential biomarker in breast cancer?
Justin M Balko, Carlos L Arteaga
Cancer Discovery
|
February 13, 2018
A Critical Need for Better Cancer Immunotherapy Models: Are Organotypic Tumor Spheroid Cultures the Answer?
Justin M Balko, Jeffrey A Sosman
Molecular Diagnosis & Therapy
|
February 21, 2012
Molecular signatures of lung cancer: defining new diagnostic and therapeutic paradigms
Justin M Balko, Carlos L Arteaga
Current Breast Cancer Reports
|
December 14, 2020
Biomarker predictors for immunotherapy benefit in breast: beyond PD-L1
Jamaal L James, Justin M Balko
Biomarkers in Medicine
|
January 18, 2018
Biomarkers for assessing the effectiveness of immunotherapy in breast cancer
Mellissa J Nixon, Justin M Balko
Med (New York, N.Y.)
|
May 19, 2022
Primed for toxicity: CD4+ T cells and immune checkpoint inhibitors
Douglas B Johnson, Justin M Balko
Cancer Biology & Therapy
|
January 26, 2011
Do the genes tell us the path of most resistance?
Justin M Balko, Ester P Black
Cancer Cell
|
March 3, 2023
T cell dynamism and immune-related adverse events
Douglas B Johnson, Justin M Balko
Page
of 18
Search research articles
Search
Showing results (1-10 of 174) with videos related to
Sort By:
Page
of 18
Cancer Cell
|
April 14, 2023
No rest for the wicked: Tumor cell senescence reshapes the immune microenvironment
Ann Hanna, Justin M Balko
Breast Cancer Research and Treatment
|
July 29, 2021
Breast cancer resistance mechanisms: challenges to immunotherapy
Ann Hanna, Justin M Balko
Breast Cancer Research and Treatment
|
August 10, 2010
Dead-box or black-box: is DDX1 a potential biomarker in breast cancer?
Justin M Balko, Carlos L Arteaga
Cancer Discovery
|
February 13, 2018
A Critical Need for Better Cancer Immunotherapy Models: Are Organotypic Tumor Spheroid Cultures the Answer?
Justin M Balko, Jeffrey A Sosman
Molecular Diagnosis & Therapy
|
February 21, 2012
Molecular signatures of lung cancer: defining new diagnostic and therapeutic paradigms
Justin M Balko, Carlos L Arteaga
Current Breast Cancer Reports
|
December 14, 2020
Biomarker predictors for immunotherapy benefit in breast: beyond PD-L1
Jamaal L James, Justin M Balko
Biomarkers in Medicine
|
January 18, 2018
Biomarkers for assessing the effectiveness of immunotherapy in breast cancer
Mellissa J Nixon, Justin M Balko
Med (New York, N.Y.)
|
May 19, 2022
Primed for toxicity: CD4+ T cells and immune checkpoint inhibitors
Douglas B Johnson, Justin M Balko
Cancer Biology & Therapy
|
January 26, 2011
Do the genes tell us the path of most resistance?
Justin M Balko, Ester P Black
Cancer Cell
|
March 3, 2023
T cell dynamism and immune-related adverse events
Douglas B Johnson, Justin M Balko
Page
of 18